{"id":"fluticasone-salmeterol-high-dose","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"3-8","effect":"Nervousness/anxiety"},{"rate":"2-5","effect":"Palpitations"},{"rate":"2-5","effect":"Muscle cramps"},{"rate":"2-5","effect":"Oral candidiasis"},{"rate":"1-3","effect":"Dysphonia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone propionate is a potent inhaled corticosteroid that suppresses inflammatory responses in the airways by binding to glucocorticoid receptors, reducing mucus production and airway edema. Salmeterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing bronchodilation and lasting up to 12 hours. The combination provides both anti-inflammatory and bronchodilatory effects for sustained asthma and COPD control.","oneSentence":"Fluticasone/Salmeterol is a combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and dilates airways to improve breathing.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:54.951Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT06572228","phase":"PHASE4","title":"Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-08-26","conditions":"Asthma","enrollment":250},{"nctId":"NCT00379288","phase":"PHASE3","title":"Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-06","conditions":"Asthma","enrollment":404},{"nctId":"NCT02437604","phase":"PHASE1","title":"Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-05","conditions":"Asthma","enrollment":43},{"nctId":"NCT02175771","phase":"PHASE3","title":"Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"Persistent Asthma","enrollment":758},{"nctId":"NCT03468790","phase":"PHASE3","title":"Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2018-05-09","conditions":"Asthma, Allergic","enrollment":393},{"nctId":"NCT03387241","phase":"PHASE3","title":"Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years","status":"UNKNOWN","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","startDate":"2017-06-02","conditions":"Asthma","enrollment":330},{"nctId":"NCT03376932","phase":"PHASE3","title":"Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2019-01-18","conditions":"Asthma","enrollment":""},{"nctId":"NCT01540708","phase":"PHASE1","title":"A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation and ROTAHALER Device for Delivery of Fluticasone Propionate/Salmeterol","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-16","conditions":"Asthma","enrollment":36},{"nctId":"NCT01961154","phase":"NA","title":"Stepping Down of Asthma Medication in Controlled Asthma","status":"COMPLETED","sponsor":"Kuopio University Hospital","startDate":"2012-10","conditions":"Asthma","enrollment":56},{"nctId":"NCT01969721","phase":"PHASE3","title":"Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":229},{"nctId":"NCT00456313","phase":"PHASE4","title":"No Resistance After Long Term Treatment SERETIDE","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2007-12","conditions":"Asthma","enrollment":""},{"nctId":"NCT01712451","phase":"PHASE2","title":"Dose-ranging Study","status":"COMPLETED","sponsor":"Neothetics, Inc","startDate":"2011-08","conditions":"Abdominal Contour Defects","enrollment":200},{"nctId":"NCT00975195","phase":"PHASE4","title":"Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2488},{"nctId":"NCT00535366","phase":"PHASE2","title":"Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":103},{"nctId":"NCT01431924","phase":"","title":"Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10","conditions":"Asthma","enrollment":7779},{"nctId":"NCT01657487","phase":"PHASE4","title":"Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients","status":"UNKNOWN","sponsor":"Far Eastern Memorial Hospital","startDate":"2010-04","conditions":"Percentage of Annual Acute Exacerbation, Quality of Life","enrollment":120},{"nctId":"NCT01647646","phase":"PHASE4","title":"Real Life Effectiveness in Patients With Not Optimally Controlled Asthma","status":"COMPLETED","sponsor":"Far Eastern Memorial Hospital","startDate":"2009-03","conditions":"Asthma","enrollment":200},{"nctId":"NCT00314574","phase":"PHASE3","title":"A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2005-12","conditions":"Asthma","enrollment":850},{"nctId":"NCT01186653","phase":"PHASE4","title":"Effect on Adrenal Function of Budesonide Versus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Hull University Teaching Hospitals NHS Trust","startDate":"2007-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":22},{"nctId":"NCT01131806","phase":"PHASE4","title":"Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2009-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":124}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["COPD patients treating with high dose of ICS (Fluticasone 1000ug/day) combined with Salmeterol (25ug/day)"],"phase":"marketed","status":"active","brandName":"Fluticasone/Salmeterol high dose","genericName":"Fluticasone/Salmeterol high dose","companyName":"Far Eastern Memorial Hospital","companyId":"far-eastern-memorial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluticasone/Salmeterol is a combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and dilates airways to improve breathing. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}